Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12745752 | 0.88 | NPC1 (0.61) | NPC1EPHX2NAAACA2ALDH1A1 | |
| SCHEMBL12745770 | 0.84 | EPHX2 (0.57) | NPC1EPHX2NAAACA2CNR2 | |
| SCHEMBL12745726 | 0.83 | EPHX2 (0.63) | NPC1EPHX2CNR2ALDH1A1POLB | |
| SCHEMBL13893813 | 0.82 | MAPT (0.48) | NPC1EPHX2NAAACA2POLB | |
| SCHEMBL12826766 | 0.82 | P2RX7 (0.53) | NPC1EPHX2NAAACA2ALDH1A1 | |
| SCHEMBL8736764 | 0.82 | EPHX2 (0.56) | EPHX2CA2ALDH1A1P2RX7 | |
| SCHEMBL12745466 | 0.82 | CYP17A1 (0.44) | NPC1EPHX2NAAA | |
| SCHEMBL12746117 | 0.82 | CNR2 (0.50) | NPC1EPHX2CNR2 | |
| SCHEMBL12745733 | 0.81 | ALDH1A1 (0.55) | NPC1ALDH1A1POLB | |
| SCHEMBL12745746 | 0.80 | EPHX2 (0.46) | NPC1EPHX2CA2CNR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | NPC1 813/4885EPHX2 312/4885NAAA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.